Glenmark receives USFDA approval for Ranolazine extended-release tablets

According to IQVIATM sales data for the 12-month period ending May 2019, the Ranexa ExtendedRelease Tablets, 500 mg and 1,000 mg market achieved annual sales of ~$929.0mn.

from India Infoline News Service https://ift.tt/2LIkoVN